The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

Published:2023-12 Issue: Volume:Volume 15 Page:899-912
ISSN:1179-1314
Container-title:Breast Cancer: Targets and Therapy
language:en
Short-container-title:BCTT

Author:

Hu Wenyu^ORCID,Wang Lei,Luo JiaLing,Zhang Jian,Li Nanlin^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference41 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Breast cancer statistics, 2019

3. Tamoxifen in the Treatment of Breast Cancer

4. Fulvestrant in advanced breast cancer: evidence to date and place in therapy

5. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

2. The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter];Breast Cancer: Targets and Therapy;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP